Stockreport

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF This August, management intends to start two late-stage studies, namely REVEAL-1 and REVEAL-2, evaluating two active dosing regimens of VRDN-003 in active and chronic T [Read more]